摘要
目的探讨依达拉奉对急性重型颅脑损伤的疗效及安全性。方法69例急性重型颅脑损伤患者,分为3组,依达拉奉治疗组32例;阳性药物对照组32例,用脑苷肌肽注射液治疗;空白对照组5例,给予常规治疗。治疗10d后,观测GCS、APACHE-Ⅱ评分及不良反应。结果与空白对照组相比,治疗组和阳性药物对照组GCS评分明显升高(P<0.05),APACHE-Ⅱ评分显著下降(P<0.01),但两组间差异无显著性。结论早期应用依达拉奉治疗急性重型颅脑损伤,可促进患者神经功能恢复,降低死亡风险,且副作用少,安全可靠。
Objective To evaluate the curative effect of edaravone on acute severe brain injury, and its safety. Metheds Sixty- nine patients with acute severe brain injury were randomly divided into three groups, i.e. treatment group （32 cases） with edaravone, positive drug control group （32 cases） receiving cattle encephalon glycoside and ignotin injection, and blank control group （5 cases） only receiving routing treatment. GCS, APACHE- Ⅱ scores and side effects were observed in all the patients 10 days after the treatment. Results The GCS significantly increased （P〈0.05） and the APACHE- Ⅱ score significantly decreased （P〈0.01） in the treatment and positive drug control groups compared to the blank control group, but there was insignificant difference in GCS and APACHE- Ⅱ score between the treatment and positive drug control groups. Conclusions Early treating acute severe brain injury with edaravone can promote recovery and decreased death risk of patients, and the side effects of edaravone is seldom.
出处
《中国临床神经外科杂志》
2006年第8期481-483,共3页
Chinese Journal of Clinical Neurosurgery
关键词
依达拉奉
急性重型颅脑损伤
氧自由基
脑苷肌肽注射液
Edaravone
Acute severe brain injury
Oxygen free radical
Cattle encephalon glycoside and ignotin injection
